ENVB - CIK 0000890821
The table below shows Enveric Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets | $5.38M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.17M |
| $3.31M |
| $4.83M |
| $4.34M |
| $5.52M |
| Property, plant & equipment | $119.93K | $196.52K | $241.08K | $267.28K | $367.69K | $405.11K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $5.52M | $4.36M | $3.55M | $5.10M | $4.79M | $6.05M |
| Accounts payable | $280.31K | $683.71K | $1.04M | $669.19K | $576.32K | $459.90K |
| Total current liabilities | $460.68K | $905.88K | $1.36M | $1.18M | $839.17K | $645.34K |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$116.48M | -$112.65M | -$110.78M | -$108.26M | -$102.92M | -$100.84M |
| Total equity | $5.06M | $3.46M | $2.18M | $3.92M | $3.95M | $5.41M |